Opendata, web and dolomites

VOGAS SIGNED

Screening of Gastric Cancer via Breath volatile organic compounds by Hybrid Sensing Approach

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 VOGAS project word cloud

Explore the words cloud of the VOGAS project. It provides you a very rough idea of what is the project "VOGAS" about.

spectrometry    sensors    cured    confounding    intestinal    schemes    compounds    invasive    headspace    coupled    breath    panels    brazil    gc    acquired    members    human    parallel    american    dimensional    exhaled    detecting    mass    data    disease    collaborations    chile    ms    gastric    spectroscopic    optimized    tool    competences    nose    orthogonal    flora    voc    metaplasia    ukraine    analytical    electronic    stage    infrared    oxide    mechanisms    vocs    geographical    precancerous    infection    cancer    bacterial    diagnosed    organic    latin    enrolled    good    validated    composition    nanoparticles    prototypes    combine    patients    clinical    atrophy    screening    mid    volatile    expertise    latvia    techniques    dysplasia    burden    chromatography    origin    compact    obtaining    building    pylori    chances    gold    lack    eastern    lesions    america    lines    cell    utilizing    device    concentration    colombia    first    components    international    countries    individuals    vital    gas    previously    portable    metal    tissue    analyser   

Project "VOGAS" data sheet

The following table provides information about the project.

Coordinator
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY 

Organization address
address: SENATE BUILDING TECHNION CITY
city: HAIFA
postcode: 32000
website: www.technion.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 3˙781˙179 €
 EC max contribution 3˙781˙179 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2021-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY IL (HAIFA) coordinator 650˙363.00
2    LATVIJAS UNIVERSITATE LV (RIGA) participant 510˙000.00
3    UNIVERSITAET INNSBRUCK AT (INNSBRUCK) participant 395˙535.00
4    UNIVERSITAET ULM DE (ULM) participant 385˙000.00
5    JLM INNOVATION GMBH DE (TUEBINGEN) participant 375˙000.00
6    Teknologian tutkimuskeskus VTT Oy FI (Espoo) participant 358˙875.00
7    UPPSALA UNIVERSITET SE (UPPSALA) participant 253˙727.00
8    UNIVERSIDAD DE PAMPLONA CO (PAMPLONA) participant 250˙625.00
9    NATIONAL CANCER INSTITUTE UA (KIYV) participant 210˙000.00
10    HOSPITAL UNIVERSITARIO SAN IGNACIO CO (BOGOTA) participant 209˙984.00
11    PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE CL (SANTIAGO) participant 182˙068.00
12    FUNDACAO ANTONIO PRUDENTE BR (SAO PAULO) participant 0.00

Map

 Project objective

Gastric cancer has good chances to be cured if diagnosed at an early stage; currently, there is lack of a reliable non-invasive screening tool. Eastern Europe and Latin America are among the geographical areas with high burden of the disease.

This project is aiming at developing a non-invasive gastric cancer screening tool by detecting characteristic panels of volatile organic compounds (VOCs). The mechanisms of VOC origin and their composition in gastric cancer patients will be addressed via headspace analysis of cancer tissue, cell-lines, and bacterial flora; VOCs identified during this analysis will be compared to the compounds present in human breath, both via gas chromatography coupled to mass spectrometry (GC-MS).

Based on this data, a new type of breath analyser will be developed and validated building upon previously acquired expertise of the consortium members. Specifically, the exhaled breath analyser will combine electronic nose concepts utilizing gold nanoparticles and metal oxide sensors with orthogonal mid-infrared spectroscopic techniques for obtaining multi-dimensional analytical data sets; furthermore, compact pre-concentration schemes will be evaluated. All components will be integrated into several prototypes of portable and optimized devices.

The clinical studies will be conducted in parallel in European (Latvia, Ukraine) and Latin American (Colombia, Brazil, Chile) countries with high disease burden. Patients with gastric cancer and individuals with and without precancerous lesions (dysplasia, atrophy, intestinal metaplasia) will be enrolled. The role of confounding factors including H.pylori infection will be addressed.

As the main result, we expect to provide the first reliable non-invasive gastric cancer screening device based on exhaled breath analysis concepts for future large-scale implementation. The development of according research competences and international collaborations therefore is the most vital component of this project.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "VOGAS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "VOGAS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

INADVANCE (2019)

Patient-centred pathways of early palliative care, supportive ecosystems and appraisal standard

Read More  

PREMSTEM (2020)

Brain injury in the premature born infant: stem cell regeneration research network

Read More  

SHIGETECVAX (2019)

Early clinical development of a live, attenuated combination vaccine against Shigella and ETEC diarrhoea

Read More